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A B S T R A C T
Given their extensive role in cell signalling, GPCRs are significant drug targets; despite this, many of these
receptors have limited or no available prophylaxis. Novel drug design and discovery significantly rely on
structure determination, of which GPCRs are typically elusive. Progress has been made thus far to produce
sufficient quantity and quality of protein for downstream analysis. As such, this review highlights the systems
available for recombinant GPCR expression, with consideration of their advantages and disadvantages, as well as
examples of receptors successfully expressed in these systems. Additionally, an overview is given on the use of
detergents and the styrene maleic acid (SMA) co-polymer for membrane solubilisation, as well as purification
techniques.
1. Introduction
As the largest family of membrane proteins in the human genome, G
protein-coupled receptors (GPCRs) are widely studied due to their in-
volvement in normotypical and pathological cell signalling profiles [1].
Characteristically, as shown in Fig. 1, these seven-transmembrane re-
ceptors undergo a conformational change upon activation by a ligand,
allowing propagation of signalling cascades within the cell [2].
Understanding the relationship between a GPCR's structure and
function will aid further development of ortho- and allosteric molecules
against these receptors to affect their pharmacology. While approxi-
mately half of all drugs target GPCRs, this is only reflected in a 5%
coverage of these receptors, providing significant scope for further
structure-based novel drug discovery [4].
While the structure of some GPCRs have been successfully de-
termined, many challenges remain in this field. These include the
concepts of homo-dimerization, heteromeric protein-protein interac-
tions and the structural complexity of important motifs [5] – of note,
the folding and flexibility of the ligand-binding domain of family B
GPCRs [6]. While computational biology has greatly enhanced the
versatility of studying GPCR structures [7], classical techniques are also
often employed including x-ray crystallography [8], cryo-electron mi-
croscopy [9] and nuclear magnetic resonance spectroscopy [10]. A
significant drawback to these methods lies in the initial requirement for
a high yield and purity of mature, folded target protein.
These challenges have propelled the development and im-
plementation of recombinant membrane protein expression, solubili-
sation and purification systems over the last two decades - contributing,
in no small part, to the increase in resolved structures of membrane
proteins in the same time-frame [11]. This review will provide a current
summary of the methodology, benefits and drawbacks of the expression
systems available to GPCR researchers (Table 1), as well as an overview
of applicable solubilisation and purification techniques.
2. Expression systems
2.1. E. coli
Native expression of GPCRs is well-known to be restricted to eu-
karyotic organisms [12] yet E. coli has proved an attractive host for
expression and purification of a subset of receptors [13]. E. coli has
become a laboratory workhorse for a number of reasons. Firstly,
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decades of work have led to well-characterised, rapidly growing cells
which are easy to culture and strains have been optimised for protein
expression, including membrane protein-specific strains [14]. E. coli can
be easily grown across a range of scales allowing fermentation to pro-
duce large quantities of protein, although it should be noted that there
is not always a linear relationship between culture volume and product
yield [14]. The genetic tractability of E. coli allows a variety of ex-
pression plasmids to be used to tune protein expression levels. This can
be particularly important with membrane proteins when saturation of
the translocon can be a rate-limiting step [13,15]. Indeed, high level
expression can lead to formation of inclusion body and refolding of
GPCRs from such environments has met with limited success [16].
Some of these problems can be overcome with judicial strain selection
and expression at lower temperatures [17]. However, due to its pro-
karyotic nature, E. coli does not possess a number of features that can be
essential for GPCR function. There is a lack of post-translational mod-
ification, including glycosylation, which can be essential for ligand
binding [18]. Despite this, there are several examples of active receptor
expression [19–34] including the neurotensin and cannabinoid CB2
receptors. The use of E. coli in this sense can also be supported by the
ability of deglycosylated receptors [35] to bind ligand, and protein
engineering for stability [36]. Additionally, the lipid membrane en-
vironment may not include essential components such as cholesterol
[37] and contains a very different lipidome to eukaryotic cells – there is
clear evidence for lipid-dependent GPCR activity [38].
Despite these clear limitations [39], there have been a number of
reports of GPCRs being successfully expressed in E. coli [19–34]. Un-
modified GPCRs tend to have low stability and may aggregate in such
systems [33]. A key strategy for successful expression and correct
folding of GPCRs in E. coli is the use of fusion partners [40]. These serve
both to direct the correct insertion of the receptor into the membrane
whilst also increasing its overall solubility, thereby aiding both ex-
pression and purification [26]. Additionally, strategies such as selective
mutagenesis to introduce stabilising mutations and the use of insertions
or truncations has proven successful in some cases [17,33]. Indeed, the
genetic tractability of E. coli can be used to select for variants with
increased stability and expression even for relatively intractable re-
ceptors [41–43].
There are a number of advantages of the use of E. coli for down-
stream applications. It is relatively easy to conduct isotopic labelling
experiments such that the subsequent protein can be used for NMR
studies [10]. It should, however, be noted that the relatively low ex-
pression levels of GPCRs in E. coli is further impacted by such labelling
strategies [10]. However, through optimised expression it has been
reported that GPCR expression of up to 50mg/L can be achieved [40].
The genetic amenability and tools available for E. coli open possibilities
to select GPCR variants with enhanced expression and stability, gen-
erate those “locked” in a particular conformation, and also to, poten-
tially, engineer those with completely novel functions [44]. Despite its
prokaryotic nature, E. coli has clear potential for at least a subset of
GPCRs.
2.2. Yeast
The fission yeast S. pombe and baker's yeast S. cerevisiae are im-
portant tools to express and investigate the signalling and stability of
GPCRs [45–51], however, the methylotrophic yeast, Pichia pastoris
(reclassified as Komagataella phaffii), is favored for the overexpression
of GPCRs for structural studies [52]. High yields of functional receptors
have been expressed [39], including the adenosine 2a receptor [53–55],
Fig. 1. Ligand induced activation of a G protein-
coupled receptor (GPCR). GPCRs (blue) are
transmembrane receptors which activate in-
tracellular signalling pathways, through coupling to
G proteins. These heterotrimeric proteins consist of
three subunits denoted α, β and γ, and are classi-
cally activated by a ligand induced conformational
change in the GPCR [2]. This movement is proposed
to involve a rotational transmembrane helix reor-
ientation, exposing an intracellular binding cleft
[3]. GDP is exchanged for GTP on Gα, while the βγ
complex splits away and is able to signal in-
dependently of the Gα subunit. Humans encode 18,
5 and 12 different α, β and γ subunits, respectively.
These combine into a variety of stimulatory (Gs) or
inhibitory (Gi/q) effects on pathways including those
dependent on adenylyl cyclase and phospholipase C.
Created with Biorender.com.
Table 1
A comparison of expression systems for GPCRs. A qualitative assessment of considerations linked to recombinant protein expression systems. Green= positive,
amber=moderate, red= negative. While E. coli and yeast were historically favourable due to ease of genetic manipulation, culture and scalability, recent devel-
opments in insect and mammalian lines have increased their use. Standard expression vectors can now be grown in litre volumes in lines including Sf9, expi293 and
expiCHO at comparable cost to produce milligram quantities of receptor. The use of Drosophila is an emerging yet promising method requiring further attention.
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5HT5A receptor, beta2-adrenergic receptor [56] and muscarinic acet-
ylcholine receptor M2 subtype (CHRM2) [57]. In addition, high-re-
solution crystal structures of the histamine H1 receptor [58] and the
adenosine 2a receptor in complex with an antibody Fab fragment [59]
have been obtained using the P. pastoris expression system as well as
other membrane proteins.
This has been feasible due to the ease of manipulation and stable
integration of expression vectors into P. pastoris coupled with its ability
to grow to high cell densities on glycerol and to utilize methanol as the
sole carbon source [60]. This system allows high levels of protein ex-
pression to be induced under the tightly controlled AOX1 promoter
[61,62]. Other promoters are also available, including the constitutive
glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter as well as
emerging novel methanol-inducible, non-methanol inducible and con-
stitutive promoters [63,64]. Several expression vectors and strains are
commercially available to optimize protein expression. Commonly used
vectors are the pPIC9K, pPICZ or pPICZalpha, the latter of which con-
tains an α-MF signal sequence derived from S. cerevisiae to enhance
protein secretion. Expression vectors generally contain geneticin, ka-
namycin or zeocin resistance genes, and auxotrophic markers have also
been used for GPCR expression [52,60]. Strains frequently used include
the wild type X-33 strain, protease deficient strains (SMD1163,
SMD1168 and SMD1165) and auxotrophic strains GS115 and KM71
[11,52,60].
P. pastoris is able to perform post translational modifications such as
disulphide bond formation, and N and O-linked glycosylation. N-linked
glycosylation occurs at the Asn-X-Ser/Thr motif on extracellular do-
mains of GPCRs [65], and in some cases is required for cell surface
expression [66], ligand binding and cell signalling [67]. While early
steps of P. pastoris N-linked glycosylation are similar to the process in
mammalian cells [68], it may potentially hypermannosylate the protein
which can lead to misfolding, although this is less extensive than in
S. cerevisiae [69]. It may also glycosylate residues of protein where this
would not naturally occur [69,70]. Some GPCRs expressed in P. pastoris
have therefore been engineered with these sites removed to facilitate
crystallisation [58,59]. A study by Yurugi-Kobayashi et al., 2009 [71]
which analysed glycosylation-deficient GPCRs demonstrated that while
some receptors were expressed with lower functional levels, others
were expressed at levels suitable for structural studies when this ap-
proach was combined with culture optimisation. P. pastoris strains and
vectors with humanized N-glycosylation have been developed [68,72],
but have not as of yet been applied to GPCR expression. Other mod-
ifications to GPCRs expressed by P. pastoris include codon optimisation,
N and C-terminal truncations [54,59] and T4-lysozyme fusion to in-
tracellular loop 3 (ICL3) [58].
In contrast to mammalian cells, yeast membranes contain ergosterol
rather than cholesterol. Membrane cholesterol is thought to be required
for the correct function of some GPCRs, and may cause direct con-
formational changes or indirectly alter membrane properties. Crystal
structures suggest that some GPCRs contain specific cholesterol binding
sites [73–75]. A humanized P. pastoris strain has been engineered which
synthesizes cholesterol [76], and could be of benefit for GPCR expres-
sion. Cholesteryl hemi-succinate, a cholesterol derivative, can also be
added to maintain stability [35, 55, 58].
In summary, yeast possess several advantages over other expression
systems, including the ability to perform eukaryotic post-translational
modifications while being capable of rapid growth to high cell densities
on a large scale in relatively cheap media [77]; these aspects make
yeast an appealing host, and their use for GPCR expression has sig-
nificantly improved knowledge of GPCR structure and function.
2.3. Insect cell-line (Sf9, Sf21, Hi5)
In GPCR structural studies, insect cells are the most commonly used
expression system to achieve milligram quantities of protein [35,78].
Expression is achieved via infection with a recombinant form of
Autographica californica; a multiple nuclear polyhedrosis virus. This
baculovirus infects the cells and drives the production of the protein of
interest, usually via the polyhedrin promoter [79]. The majority of
GPCR studies use the Spodoptera frugiperda (Sf9) or Sf21 cell-line, in
preference to Trichoplusia ni (High Five) cells [78]. However protein
expression levels can vary between different cell-lines so screening of
cell lines is necessary when using insect cells for structural studies. The
advantages of insect cell expression include growth in serum-free
shaker cultures, which decreases costs and enables relatively easy scale-
up, as well as high yield and the ability to perform most post-transla-
tional modifications [79].
A range of different systems have been developed to generate the
recombinant baculovirus [79]. Once generated the virus requires ti-
tration in order to achieve an appropriate multiplicity of infection
(MOI); an excess of virus will kill the cells before they can be harvested
[79]. This step is often the most difficult as how to directly quantify
virus is unclear and often inaccurate. Viral plaque assays are commonly
used but take a minimum of two weeks and, often, their accuracy is
questionable [79]. Various alternative approaches have been devised,
including flow cytometry and qPCR, but cost, time and variability can
still be problematic [80]. Many researchers find that using the virus
directly to express protein in Sf9 cells and quantifying the expression
level is quicker and more accurate. However, once the virus has been
generated and titrated it can be stored for a number of years at 4 °C and
much longer at −80 °C. More virus can also be generated by infecting
the cells with a high MOI and collecting the cell culture media five days
post-infection [81]. Initially, it can take up to a month to produce en-
ough baculovirus to drive large scale expression however, once the
virus has been generated, protein can be expressed within a week.
One potential disadvantage of insect cell expression arises from
differences in lipid composition compared to mammalian cells. Insect
cell membranes are low in cholesterol, have very high phosphatidyli-
nositol content and no phosphatidylserine [35], and as noted below,
protein function is highly dependent on lipid environment [82]. There
have also been reports that a proportion of the protein produced can be
misfolded [83], or that the lytic pathway of viral infection can cause
protein degradation [81]. However, overall it remains one of the key
approaches for GPCR overexpression.
2.4. Mammalian cell-line (HEK293, COS)
Membrane proteins are often expressed in insect, bacterial or yeast
expression systems due to their high protein yield and expression,
which is advantageous for structural studies [84]. High resolution
human membrane protein structures have been solved from re-
combinant proteins derived from these sources, but the protein con-
formation and modifications may differ from a human protein ex-
pressed in human cells. To address these issues, mammalian cell-lines
capable of expressing a desired protein have been trialled [85]. The
selection of a specific cell-line is determined by whether the expression
system represents the near-native environment in which the desired
protein is endogenously expressed [84]. GPCRs are heavily post-trans-
lationally modified, therefore expressing human GPCRs in mammalian
cells is often ideal to characterise their function and pharmacology
[35]. For structural biology however, post-translational modifications
can be detrimental during crystal formation. Glycosylation sites affect
formation of ordered crystals due to the flexibility and heterogeneity of
glycan residues [35]. This issue can be solved by mutating the N-gly-
cosylation sites, provided that the conformation of the receptor is still
stable [35]. Alternatively, the use of the GnTI− line which lacks N-
acetylglucosaminyl transferase I activity would possibly enable further
control of complex glycans [86].
The native environment in which GPCRs are expressed has an im-
pact on the conformation and pharmacology of these receptors. The
phospholipid composition of the native lipid bilayer has an allosteric
effect on GPCRs. In the case of the human beta 2 adrenergic receptor in
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different liposomes, synthetic phosphatidylglycerol stabilised the active
conformation of the receptor [82]. Due to variations in lipid composi-
tion between cell-lines of different expression systems, choosing a
human cell-line that has a similar lipid composition to that of the en-
dogenous GPCR is important for receptor pharmacology. As cholesterol
can allosterically modulate GPCRs [87], its replacement with ergosterol
in yeast expression systems can be detrimental. In the case of the
human μ-opioid GPCR, ergosterol constrain the receptor in an inactive
state, whereas cholesterol stabilises the active state [88]. Post-transla-
tional modification is important for GPCR function, where mammalian
cells have the correct enzymes for phosphorylation and palmitoylation
of human GPCRs [35].
Yields of recombinant protein in non-mammalian expression sys-
tems are often higher than mammalian expression systems, therefore
optimising the GPCR gene construct for expression is an important first
step [35]. Note, however, that higher levels of expression does not
necessarily correlate with functional expression and a robust assay for
ligand binding and/or signalling can be essential in any optimisation
process [83]. This may take the form of traditional radioligand or
fluorescent binding assay or could employ NanoBRET e.g. using β1AR
tagged with NanoLuc at the N terminus [89]. In any case, GPCR gene
constructs are often codon optimised for mammalian cell expression
[90]. Kozak sequences (GCCACCATGG) and signal peptide sequences
can be fused to the 5‘ end of the GPCR construct to enhance protein
expression and cell surface delivery [90,91]. Subsequently, the opti-
mised construct can be ligated into a plasmid vector, which can be
transfected into mammalian cells transiently, or be used to create stable
cell lines [35]. While transient transfections with popular reagents give
detectable expression at the 48 h mark (on average), this can be ex-
tended. The BacMam technology uses a modified baculovirus to give
expression within 4–6 h of transduction, lasting up to 5–14 days [92].
Finally, not only are stable lines more reproducible in terms of ex-
pression levels, inducible lines have been shown to improve the correct
folding of GPCRs when compared to insect cells [83].
Overall, immortalised mammalian cell-lines are useful to study
human GPCRs in their wild-type or mutated form. The immortalised
human embryonic kidney 293 (HEK293) can transiently express re-
combinant proteins and is amongst the most popular human cell-line to
use [93,94]. HEK293 cells exist as adherent cells or suspension cells; the
latter are grown at a higher density, which is useful for protein pro-
duction [93]. Table 2 summarises the currently known 3D structures of
GPCRs derived from expression in mammalian cell-lines, as of 30/8/19.
2.5. Drosophila melanogaster
Each of the conventional expression systems detailed above are not
without their limitations. One of the major drawbacks associated with
all of these systems is the build-up of immature proteins in the in-
tracellular membranes caused by the cell's failure to properly fold and
transport the mature GPCR to the cell surface. This issue can lead to
inadequate yields for structural studies thus limiting our understanding
of GPCR structure and function [95,96] and obtaining adequate yields
of the mature GPCR often requires optimisation of the expression
conditions, increasing cost.
The fruit-fly, Drosophila melanogaster, has recently been utilised as
an attractive alternative expression system to overcome some of these
problems. The system takes advantage of the unique properties and
architecture of the fly eye which consists of photoreceptor cells (PRCs)
containing membrane stacks called rhabdomeres [97] therefore pro-
viding a large surface area for expression and folding of large amounts
of membrane-associated proteins [98].
Heterologous expression of proteins within the PRCs is achieved
using the well-established GAL4-UAS system [99]. This system allows
the tissue-specific expression of transgenes by exploiting the use of the
yeast GAL4 protein, a transcription factor that specifically binds to an
Upstream Activating Sequence (UAS) to drive expression of its target
genes. To express a specific protein in a particular tissue type within the
fly, two strains are mated together: the driver-strain which expresses
GAL4 from a tissue-specific promoter and the UAS strain which con-
tains the transgene of interest cloned downstream of the GAL4 UAS
(Fig. 2). In the resulting offspring, the transgene will be expressed in
those specific cells that contain GAL4 [99]. By using a driver-strain that
specifically expresses GAL4 within the fly eye, heterologous GPCR ex-
pression can be restricted to the PRCs. Generating transgenic flies is
relatively easy and comparable in cost to other conventional expression
systems. Also, Drosophila culture media for rearing experimental ani-
mals is relatively inexpensive and the need to work in sterile conditions
is eliminated when working with flies [98].
Drosophila PRCs have been successfully used to express a number of
GPCRs [100]; the Drosophila metabotropic glutamate receptor,
DmGluRA being first reported. Overexpression of DmGluRA in PRCs
resulted in higher yields of mature receptor than obtained using other
conventional methods, including insect cell culture. Moreover, toxicity
effects of DmGluRA overexpression were not observed in the host cells,
overcoming a major limitation of other expression systems. Expressing
mammalian mGluRs in the fly eye produced similar yields as expressing
DmGluRA, suggesting that this system can be used to express foreign
GPCRs from other species including human, rat and Chlamydomonas
[98]. Furthermore, expression of the other two classes of GPCRs have
now also been successfully reported using this system [100]. Im-
portantly, it should also be noted that scale-up of expression, as re-
quired for downstream processes such as crystallisation, can be readily
achieved and can sometimes be an issue for other cell culture-based
expression systems [77].
Although the use of Drosophila for GPCR expression overcomes
several of the major drawbacks associated with more conventional
expression systems, it is not without its own limitations. Firstly, this
method requires access to fly genetics expertise and facilities for
Drosophila culture that if unavailable will require the need for colla-
boration with specialised laboratories that can provide these services
[98]. Additionally, although this system is capable of post-translation-
ally modifying proteins there are differences in some of the modifica-
tions that occur in the fly that may be important for GPCR function. An
example of this is N-glycosylation, which tends to be less complex in
insects and lacking in extended antennae compared to mammals
[101,102]. Furthermore, regarding purification of membrane-asso-
ciated proteins expressed in the fly eye, there is currently a lack of
reports describing the use of detergent-free purification methods such
as SMALPs using this system [98,100]. This will be an important future
Table 2
3D structures of recombinant GPCRs derived from mammalian cell-line
expression. Database query generated with MemProtMD at https://blanco.
biomol.uci.edu/mpstruc/Accessed 5/9/19.
GPCR Organism Cell-Line Resolution, Å PDB Entry
Angiotensin type II
receptor
H. sapiens Expi293F 2.90 6DO1
CB1 cannabinoid
receptor
H. sapiens HEK293F 2.80 5TGZ
Cytomegalovirus US28 H. sapiens HEK 2.89 4XT1
Leukotriene B4
receptor
C. porcellus HEK293 3.70 5X33
Rhodopsin B. taurus Cos 3.40 2J4Y
HEK293S-
GnTI-
3.30 4A4M
HEK293S 2.36 6FK6
HEK293 4.38 6QNO
H. sapiens HEK293S 3.30 4ZWJ
H. adansoni HEK293 2.14 6I9K
Smoothened receptor H. sapiens HEK293S-
GnTI-
3.20 5L7D
HEK293S 3.84 6OT0
M. musculus HEK293 2.80 6O3C
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development due to the problems of membrane protein stabilisation
associated with using detergents [103,104]. Yet despite these apparent
shortfalls, Drosophila could prove to be a cheaper and more efficient
alternative for functional GPCR expression and purification.
3. Solubilisation and purification
3.1. Detergents
An important barrier to studying GPCRs is the need to solubilise and
purify these membrane proteins away from their native bilayer [105].
Ideally, this process should simultaneously retain target proteins in
their folded, functional conformations for further in vitro study. Sur-
factant detergents are able to solubilise and extract membrane proteins
due to their amphiphilic nature, improving the aqueous solubility of the
protein [106]. A plethora of detergents are commercially available with
different physicochemical properties; often, a screen is best performed
to identify optimal detergents, likely on a protein-by-protein basis
[107].
Briefly, detergents fall into three classes based on their polar head
group – ionic, zwitterionic and non-ionic. Ionic detergents such as SDS
are regarded as harsh, zwitterions are milder (LDAO) while non-ionic
detergents are considered mild. The described harshness is derived from
the efficacy of disrupting intra- and inter-molecular interactions. While
some factors can be scrutinised, such as the critical micelle concentra-
tion (CMC) and hydrophilic-lipophilic balance (HLB), some detergents
clearly perform well [108]. Overall, the non-ionic alkyl maltopyrano-
side detergents DM and DDM have been most successful in contributing
Fig. 2. The Drosophila GAL4-UAS system for tar-
geted gene expression. The GAL4-UAS system can
be used for targeted expression of GPCRs within the
Drosophila photoreceptor cells (PRCs). To obtain
flies expressing a gene of interest in a tissue specific
pattern, two Drosophila strains are mated together in
the parental cross. The driver strain expresses the
yeast GAL4 protein from a tissue-specific enhancer/
promoter. The UAS strain contains the gene of in-
terest cloned downstream of the GAL4 Upstream
Activating Sequence (UAS). The resulting F1 off-
spring will express GAL4 protein in a tissue-re-
stricted pattern which will bind to the UAS se-
quences upstream of the gene of interest to drive its
expression in those specific cells. By using a driver
strain that expresses GAL4 specifically within the fly
eye, heterologous GPCR expression can be restricted
to the PRCs.
Fig. 3. Solubilised GPCR in a detergent micelle
compared to a SMALP. These diagrams show the
interactions of the phospholipid bilayer (grey) or
detergent monomers (red) with a GPCR (blue).
Importantly, the difference between a detergent
micelle and SMALP is shown, with regards to the
retention of the GPCR's annular lipids when sur-
rounded by the SMA co-polymer (purple). Created
with Biorender.com.
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to the resolution of membrane protein structures (approximately 45%)
[109], and can be regarded as an evidence-based starting point
[11,55,58,59,110].
Detergent monomers will, above the CMC, associate with a biolo-
gical membrane and undergo a transbilayer mechanism to flip from the
outer to inner leaflet [111]. This leads to the formation of lipid-de-
tergent micelles (Fig. 3), the efficacy of which depends on the HLB and
size/polarity of the detergent molecule. At this point, the bilayer falls
apart resulting in the solubilisation of the membrane. A GPCR's pro-
trusion from the bilayer can aid in the incorporation of detergent
monomers due to disruptions in the ordered lipid arrangement. How-
ever, this can be opposed by the notion of detergent-resistant mem-
branes [112] – especially in regards to GPCR populations in cholesterol-
rich lipid rafts [113].
Following solubilisation, it is often necessary to reduce or remove
excess detergent to enable purification and further structural or func-
tional analysis. Several methods are sufficient to achieve this including
dialysis, size exclusion and affinity chromatography [111].
Despite their utility thus far, detergents are not without their lim-
itations. Understanding of GPCR structure/function has led to the ac-
knowledgement of the native lipid environment. Not only do the lipids
surrounding a receptor provide lateral pressure, directly bound lipids
can also be essential to influence active/inactive conformations [55]. As
such, detergent micelles do not exert the same lateral pressure, and in
some cases, the directly bound lipids required for stability/function are
removed. It is therefore preferential to adopt techniques which retain
these important components to represent a more biologically realistic
reflection of GPCRs and their surroundings; and to prevent destabili-
sation or inactivation during solubilisation [114].
While several new detergents are being designed/developed, other
advances reviewed elsewhere include amphipols [115], nano discs
[116] and co-polymers including DIBMA [117] and SMA [118]. Lar-
gely, detergents must be chosen empirically, which can be an expensive
and protein-demanding approach.
3.2. SMALPs
GPCRs are one of the classes of protein that have most frequently
defied the attempts by biochemists to purify and characterise them.
Poor thermal stability is often blamed for this, and considerable effort
and resources have been expended to generate thermostabilized ver-
sions of GPCRs, in particular for structural studies [119]. An alternative
outlook is that GPCRs are destabilised by detergents. Replacing these
with better membrane mimetics could prevent destabilisation of the
proteins. Amongst the alternatives that have been proposed to meet this
need are styrene maleic acid lipid particles (SMALPs). Styrene maleic
acid (SMA) is an amphipathic co-polymer that, when added to lipids,
spontaneously assembles into nanoparticles of ∼10 nm diameter
[120,121]. These nanoparticles consist of SMA polymer surrounding a
patch of lipid bilayer (Fig. 3). When SMA is added to biological mem-
branes a similar self-assembly process forms polymer-bound lipid par-
ticles containing membrane proteins [122–126].
One of the first reported successes using the SMALP method was the
purification and functional characterisation of the adenosine-2A re-
ceptor (A2AR) which was overexpressed in both human epithelial
kidney (HEK) cells and Pichia pastoris (Table 3) [55]. This demonstrated
that the protein could be rapidly and effectively purified in a detergent-
free manner.
The ligand-binding properties of the A2AR-SMALPs were used to
assay its stability under a variety of conditions. Notably, A2AR-SMALPs
withstood more than 5 freeze-thaw cycles without reduction in their
ligand binding ability. Likewise, A2AR-SMALPs and A2AR in the mem-
brane both retained 75% of their specific ligand binding capacity after
up to 15 days of incubation at 4 °C. In detergent, this binding declined
to 0% by day 3. Similarly at 37 °C the stability of A2AR in SMALPs far
outstripped that of the detergent-solubilised sample. This remarkable Ta
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stability under a range of conditions makes A2AR-SMALPs a much more
flexible and useful reagent than the detergent-solubilised equivalent.
A2AR was also used in a study of an alternative styrene co-polymer:
styrene maleimide (SMI). This has some similar properties and archi-
tecture to SMA, but is acid-compatible and can be used in buffers with
pH < 7.8 [127]. By contrast SMA is soluble only above pH 5.8, and is
more usually used in buffers of pH 8. A2AR-SMILPs had ligand-binding
properties equivalent to the protein in the cell membrane, indicating
that SMI also has potential as a reagent for the detergent-free pur-
ification of GPCRs. In the same study, the vasopressin receptor (V1aR)
also retained its specific ligand-binding properties in SMILPs.
The ability to bind ligands is not the only indicator of GPCR function.
Perhaps of more importance is the ability of a purified GPCR to recruit/
signal to G-proteins and initiate intracellular signalling cascades [128].
One study using SMA has demonstrated that the melatonin receptor
(MT1R) and the ghrelin receptor (GHS-R1a) in SMALPs are capable of G-
protein activation, arrestin recruitment and ligand binding [129].
To date, there is only one high resolution structure of a GPCR in
SMALPs, Haloquadratum walsbyi bacteriorhodopsin (HWbR). This struc-
ture was solved at 2.0 Å resolution using the in meso crystallisation (lipidic
cubic phase) methodology [130]. Hence, it is likely that the protein-
SMALPs integrated into the bilayers of the cubic phase prior to crystal-
logenesis. Lipids are visible in the structure, but these are identifiable as
monooleins, the lipids used to assemble the cubic phase. In a parallel
experiment, bR purified using detergent had a remarkably similar struc-
ture to the structure derived from SMA-solubilised bR. Therefore in this
case there is an argument that using SMA did not provide additional
structural information compared to using detergent. By contrast, a recent
structure was solved by cryo-electron microscopy at 3.4 Å resolution of a
bacterial respiratory supercomplex purified using SMA [131]. This struc-
ture did show specific native lipids bound to the protein, which may be of
relevance in understanding the subtleties of its structure and function. This
hints that cryo-EM may be a viable approach for solving structures of
membrane proteins retaining their native lipids.
Following solubilisation, several purification methods may be em-
ployed which have been reviewed elsewhere [132]. Summarised in
Table 4, these include gel filtration, ion exchange and affinity chro-
matography, of which the latter is most popular. While affinity to an-
tibodies or ligands such as lectin can be utilised for membrane proteins,
GPCRs expressed in the systems discussed have utilised a range of
purification tags. These include poly-histidine [55,58], FLAG [56,133],
HA [134], Strep-Tactin [135], Rho [136] and EF1 [137] tags among
others. Following detection and affinity chromatography purification, it
is possible to obtain the quantities of functional material required for
structural studies with these tags [58,59].
More recent advancements include the use of mini-G proteins to
study GPCRs in their active conformations [138]. These are engineered
GTPase domains of the Gα subunits of G proteins and stabilise the ac-
tive conformation of the receptor. Not only have they been shown to
form stable complexes purified by SEC, N-terminal fusion with GFP
allows for successful detection of coupling by FSEC [138]. Such re-
agents provide huge potential for state-selective purifications.
4. Conclusion
GPCRs remain a challenging component of the membrane protein
structural biology field. While the sources of difficulty are gradually being
lessened as understanding and technology advance, the dearth of struc-
tural information is limiting novel drug design and discovery [4]. Com-
putational biology has greatly enhanced the ability to predict and ma-
nipulate GPCR structure, and how this affects their functions. However, in
silico experiments remain only a component of the holistic study of
membrane proteins; expression and purification are largely required be-
fore downstream biochemical and biophysical analysis [8,9,143,144].
As such, and discussed in this review, the expression systems
available to GPCR researchers each come with their own benefits and
drawbacks. While ease of culture and genetic amenability are un-
doubtedly attractive qualities, they clearly do not entirely make up for
biologically important characteristics such as post-translational mod-
ifications. There will always seemingly remain a compromise with the
expression system of choice, if only the expense. Regardless of these
drawbacks, each traditional system will be preferred for application to
certain techniques. For example, post-translational modification may be
less desired with regards to crystallisation, but more so for trafficking
and functionality.
An interesting alternative to consider is cell-free expression [145].
As cell lysate is used, problems such as toxicity and sequestering of
protein to inclusion bodies is avoided. Additionally, this technique al-
lows for modification of GPCRs with unnatural amino acids [146] and is
a useful method for NMR labelling [10]. Finally, expression in the eyes
of Drosophila offers a promising solution for a scalable production of
functional recombinant membrane proteins (Table 5). Currently, as of
September 2019, only five PDB entries were derived from expression in
Drosophila – none of which were GPCRs. Future work to broaden the
Table 4
Pros and cons of purification techniques available for GPCRs.
Purification Technique Pros Cons
Affinity chromatography [139,140] Can be used if protein molecular weight, charge or hydrophobicity is unknown.
High affinity binding can result in high sample purity.
May require a tag or terminal fusion.
Washing may remove weakly bound molecules.
SMALPs are sensitive to divalent cations.
Gel filtration [141,142] Efficient separation of large and small molecules.
Minimal elution volume.
No sample loss.
Only separated on size.
May require further techniques.
Limited resolution due to short chromatogram timescale.
Ion exchange [139] Only one charge-based interaction.
Predictable elution pattern.
Inconsistency between columns.
Limited to ionizable groups.
Table 5
Expression levels of recombinant GPCRs in the photoreceptor cells of Drosophila melanogaster. Data obtained from Panneels et al., 2011
[98]. MP=membrane protein.
GPCR Organism Expression level, pmol/mg total MP
CCR5 Chemokine receptor H. sapiens 555
DmGluRA Metabotropic glutamate receptor D. melanogaster 226
mGluR5 Metabotropic glutamate receptor R. norvegicus 192
Rh1 Rhodopsin D. melanogaster 502
V2R Vasopressin receptor H. sapiens >1000
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diversity and characterisation of varied GPCRs would invaluably re-
inforce the use of this emerging technique. Overall, the field is currently
in a much stronger position than a few decades ago, and will un-
doubtedly continue to build upon the methods reviewed here.
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